Evidence map›Paper›PMID 42307233›Full record

Trial reportAntimicrobial agents and chemotherapy2026

Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers.

Bjørg Bolstad, Ragnar Hovland, Johan Bylund, Erik Rein-Hedin, Sandra Kuusk, Bjørn Klem, Pål Rongved

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bjørg BolstadAdjuTec Pharma AS, Oslo, Norway.ORCID 0009-0007-9064-932X
Ragnar HovlandAdjuTec Pharma AS, Oslo, Norway.
Johan BylundClinical Trial Consultants AB, Uppsala, Sweden.
Erik Rein-HedinClinical Trial Consultants AB, Uppsala, Sweden.
Sandra KuuskClinical Trial Consultants AB, Uppsala, Sweden.
Bjørn KlemAdjuTec Pharma AS, Oslo, Norway.
Pål RongvedAdjuTec Pharma AS, Oslo, Norway.ORCID 0000-0001-6678-1952

Funding

Eurostars Eurostars 3 - Call1 - 132Norges Forskningsråd Eurostars 3 - Call1 - 132VINNOVA Eurostars 3 - Call1 - 132
6 · The paper itself

Abstract

APC148 is a novel metallo-β-lactamase inhibitor with broad activity against Ambler class B enzymes, including NDM, VIM, and IMP. It is being developed for patients with serious infections caused by multidrug-resistant, gram-negative bacteria. APC148 is combined with the broad-spectrum β-lactam antibiotic meropenem and the serine-β-lactamase inhibitor avibactam, which targets Ambler class A, C, and some class D (OXA-48-like) enzymes. In combination with meropenem and avibactam, APC148 demonstrated superior

Indexed as

Anti-Bacterial Agentsbeta-Lactamase InhibitorsAdultAzabicyclo Compoundsbeta-LactamasesFemaleHealthy VolunteersHumansMaleMeropenemMicrobial Sensitivity TestsMiddle AgedThienamycinsYoung AdultAnti-Bacterial AgentsavibactamAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesMeropenemThienamycinsAPC148metallo β-lactamasespharmacokineticsphase 1β-lactamase inhibitor

Identifiers

PMID42307233
PMCPMC13435678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.